Skip to main content
Figure 2 | BMC Pulmonary Medicine

Figure 2

From: Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study

Figure 2

Mean treatment differences for change from baseline in 1-hour post-dose FEV 1 . (a) At Week 24; (b) Over 24 weeks; Data are presented as least squares means (SE) for the ITT population. ***p < 0.001 vs placebo; ‡p < 0.05; ‡‡‡p < 0.001 vs aclidinium; †††p < 0.001 vs formoterol; §p < 0.05; §§p < 0.01 vs FDC 400/6 μg. FDC, aclidinium/formoterol fixed-dose combination; FEV1, forced expiratory volume in 1 second; ITT, intent-to-treat; SE, standard error.

Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us